Coherus Biosciences Inc (NASDAQ:CHRS) has been given an average recommendation of “Buy” by the eleven analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $32.00.
A number of equities analysts have issued reports on the company. Citigroup reiterated a “buy” rating and issued a $23.00 price objective on shares of Coherus Biosciences in a report on Tuesday, November 7th. ValuEngine downgraded Coherus Biosciences from a “sell” rating to a “strong sell” rating in a report on Thursday, October 26th. Credit Suisse Group reiterated an “outperform” rating and issued a $17.00 price objective (down previously from $24.00) on shares of Coherus Biosciences in a report on Wednesday, September 27th. Zacks Investment Research upgraded Coherus Biosciences from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Wednesday, January 3rd. Finally, BidaskClub upgraded Coherus Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, December 21st.
Large investors have recently modified their holdings of the company. Temasek Holdings Private Ltd bought a new position in shares of Coherus Biosciences during the third quarter valued at $87,524,000. New York State Common Retirement Fund increased its holdings in shares of Coherus Biosciences by 32.1% during the second quarter. New York State Common Retirement Fund now owns 43,600 shares of the biotechnology company’s stock valued at $626,000 after acquiring an additional 10,599 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in shares of Coherus Biosciences during the second quarter valued at $602,000. Northern Trust Corp increased its holdings in shares of Coherus Biosciences by 13.8% during the second quarter. Northern Trust Corp now owns 464,056 shares of the biotechnology company’s stock valued at $6,660,000 after acquiring an additional 56,122 shares in the last quarter. Finally, FMR LLC increased its holdings in shares of Coherus Biosciences by 0.3% during the second quarter. FMR LLC now owns 7,693,124 shares of the biotechnology company’s stock valued at $110,396,000 after acquiring an additional 21,143 shares in the last quarter. Hedge funds and other institutional investors own 81.00% of the company’s stock.
Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. sell-side analysts predict that Coherus Biosciences will post -4.39 EPS for the current fiscal year.
WARNING: “Coherus Biosciences Inc (CHRS) Given Average Rating of “Buy” by Analysts” was originally published by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://baseballnewssource.com/markets/coherus-biosciences-inc-chrs-given-average-rating-of-buy-by-analysts/1848567.html.
About Coherus Biosciences
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.